Mark D Stewart

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4716172/publications.pdf

Version: 2024-02-01

22 papers	1,278 citations	858243 12 h-index	843174 20 g-index
22 all docs	22 docs citations	22 times ranked	1938 citing authors

#	Article	IF	Citations
1	Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies. Clinical Cancer Research, 2023, 29, 2371-2374.	3.2	0
2	Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer. Journal of Biopharmaceutical Statistics, 2022, 32, 204-218.	0.4	5
3	Homologous Recombination Deficiency: Concepts, Definitions, and Assays. Oncologist, 2022, 27, 167-174.	1.9	69
4	Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials. Cytotherapy, 2022, 24, 742-749.	0.3	2
5	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. Clinical Cancer Research, 2021, 27, 2416-2423.	3.2	18
6	Expedited Development Programs at the Food and Drug Administration: Insights and Opportunities. Therapeutic Innovation and Regulatory Science, 2021, 55, 619-621.	0.8	2
7	Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCOâ€“Friends of Cancer Research Joint Research Statement. Clinical Cancer Research, 2021, 27, 2394-2399.	3.2	47
8	Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Annals of Oncology, 2021, 32, 1626-1636.	0.6	86
9	Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England. JCO Clinical Cancer Informatics, 2021, 5, 1155-1168.	1.0	8
10	Heparanase promotes myeloma stemness and in vivo tumorigenesis. Matrix Biology, 2020, 88, 53-68.	1.5	24
11	How Oncologists Perceive the Availability and Quality of Information Generated From Patient-Reported Outcomes (PROs). Journal of Patient Experience, 2020, 7, 217-224.	0.4	1
12	International liquid biopsy standardization alliance white paper. Critical Reviews in Oncology/Hematology, 2020, 156, 103112.	2.0	66
13	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations ofÂtheÂQuality in Pathology Study. Journal of Thoracic Oncology, 2020, 15, 1177-1189.	0.5	81
14	Accelerating the development of innovative cellular therapy products for the treatment of cancer. Cytotherapy, 2020, 22, 239-246.	0.3	7
15	Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. , 2020, 8, e000147.		329
16	Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols. Therapeutic Innovation and Regulatory Science, 2019, 53, 270-278.	0.8	22
17	An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer. JCO Clinical Cancer Informatics, 2019, 3, 1-15.	1.0	81
18	Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes and Cancer, 2019, 58, 578-588.	1.5	173

#	Article	IF	Citations
19	Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice. Therapeutic Innovation and Regulatory Science, 2018, 52, 771-777.	0.8	7
20	Heparan sulfate in the nucleus and its control of cellular functions. Matrix Biology, 2014, 35, 56-59.	1.5	93
21	The heparanase/syndecanâ€1 axis in cancer: mechanisms and therapies. FEBS Journal, 2013, 280, 2294-2306.	2.2	156
22	Shed syndecanâ€1 drives tumor progression by binding to the cell surface and translocating to the nucleus. FASEB Journal, 2013, 27, 595.1.	0.2	1